Visgeneer (4197) - Net Assets

Latest as of December 2025: NT$199.09 Million TWD ≈ $6.27 Million USD

Based on the latest financial reports, Visgeneer (4197) has net assets worth NT$199.09 Million TWD (≈ $6.27 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$335.03 Million ≈ $10.56 Million USD) and total liabilities (NT$135.94 Million ≈ $4.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Visgeneer tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets NT$199.09 Million
% of Total Assets 59.42%
Annual Growth Rate 0.03%
5-Year Change -9.01%
10-Year Change -36.13%
Growth Volatility 10.45

Visgeneer - Net Assets Trend (2011–2025)

This chart illustrates how Visgeneer's net assets have evolved over time, based on quarterly financial data. See Visgeneer (4197) defensive interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Visgeneer (2011–2025)

The table below shows the annual net assets of Visgeneer from 2011 to 2025. For live valuation and market cap data, see 4197 company net worth.

Year Net Assets Change
2025-12-31 NT$199.09 Million
≈ $6.27 Million
+2.71%
2024-12-31 NT$193.84 Million
≈ $6.11 Million
-8.38%
2023-12-31 NT$211.57 Million
≈ $6.67 Million
-8.47%
2022-12-31 NT$231.16 Million
≈ $7.28 Million
+5.64%
2021-12-31 NT$218.81 Million
≈ $6.89 Million
+0.38%
2020-12-31 NT$218.00 Million
≈ $6.87 Million
+0.28%
2019-12-31 NT$217.39 Million
≈ $6.85 Million
-12.75%
2018-12-31 NT$249.15 Million
≈ $7.85 Million
-11.35%
2017-12-31 NT$281.04 Million
≈ $8.85 Million
-9.84%
2016-12-31 NT$311.69 Million
≈ $9.82 Million
-1.27%
2015-12-31 NT$315.69 Million
≈ $9.95 Million
+2.08%
2014-12-31 NT$309.25 Million
≈ $9.74 Million
+8.28%
2013-12-31 NT$285.60 Million
≈ $9.00 Million
+14.14%
2012-12-31 NT$250.23 Million
≈ $7.88 Million
+26.23%
2011-12-31 NT$198.23 Million
≈ $6.25 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Visgeneer's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 11281300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components NT$311.90 Million 156.66%
Total Equity NT$199.09 Million 100.00%

Visgeneer Competitors by Market Cap

The table below lists competitors of Visgeneer ranked by their market capitalization.

Company Market Cap
E-H.(CH)ENT. H. DL-00001
F:1VC
$8.18 Million
Era Graharealty PT Tbk
JK:IPAC
$8.18 Million
Yelooo Integra Datanet Tbk PT
JK:YELO
$8.18 Million
Arbor Metals Corp
V:ABR
$8.19 Million
High Arctic Energy Services Inc.
TO:HWO
$8.17 Million
Taitron Components Incorporated
NASDAQ:TAIT
$8.17 Million
Aumake Ltd
AU:AUK
$8.17 Million
ENDRA Life Sciences Inc
NASDAQ:NDRA
$8.16 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Visgeneer's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 193,842,000 to 199,089,000, a change of 5,247,000 (2.7%).
  • Net income of 5,247,000 contributed positively to equity growth.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income NT$5.25 Million +2.64%
Total Change NT$- 2.71%

Book Value vs Market Value Analysis

This analysis compares Visgeneer's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.30x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.92x to 1.30x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 NT$9.31 NT$8.60 x
2018-12-31 NT$8.26 NT$8.60 x
2019-12-31 NT$7.20 NT$8.60 x
2020-12-31 NT$7.22 NT$8.60 x
2021-12-31 NT$7.25 NT$8.60 x
2022-12-31 NT$7.66 NT$8.60 x
2023-12-31 NT$7.01 NT$8.60 x
2024-12-31 NT$6.42 NT$8.60 x
2025-12-31 NT$6.60 NT$8.60 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Visgeneer utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.64%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 2.93%
  • • Asset Turnover: 0.53x
  • • Equity Multiplier: 1.68x
  • Recent ROE (2.64%) is above the historical average (-1.78%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 11.28% 16.10% 0.60x 1.16x NT$3.66 Million
2014 6.54% 9.97% 0.53x 1.23x NT$-10.71 Million
2015 7.06% 10.77% 0.38x 1.71x NT$-9.28 Million
2016 0.12% 0.23% 0.31x 1.67x NT$-30.79 Million
2017 -10.91% -19.45% 0.29x 1.95x NT$-58.76 Million
2018 -12.80% -22.37% 0.32x 1.81x NT$-56.80 Million
2019 -14.61% -20.89% 0.32x 2.21x NT$-53.49 Million
2020 0.28% 0.34% 0.38x 2.12x NT$-21.20 Million
2021 0.37% 0.50% 0.39x 1.95x NT$-21.06 Million
2022 5.34% 7.82% 0.32x 2.11x NT$-10.77 Million
2023 -9.26% -13.24% 0.37x 1.88x NT$-40.75 Million
2024 -9.15% -15.32% 0.35x 1.71x NT$-37.11 Million
2025 2.64% 2.93% 0.53x 1.68x NT$-14.66 Million

Industry Comparison

This section compares Visgeneer's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,605,275,000
  • Average return on equity (ROE) among peers: 6.79%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Visgeneer (4197) NT$199.09 Million 11.28% 0.68x $8.18 Million
Apex Biotechnology Corp (1733) $1.75 Billion 11.53% 0.52x $92.11 Million
Sinphar Pharmaceutical Co Ltd (1734) $1.32 Billion 9.26% 0.78x $190.85 Million
Panion & BF Biotech Inc (1760) $1.93 Billion 5.40% 0.53x $161.80 Million
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) $2.50 Billion 21.29% 0.26x $85.54 Million
SYN-Tech Chem & Pharm Co Ltd (1777) $969.06 Million 16.12% 0.26x $101.71 Million
Level Biotechnology (3118) $542.40 Million 10.78% 0.50x $31.95 Million
GenMont Biotech Inc (3164) $737.87 Million 20.00% 0.85x $44.44 Million
Medigen Biotechnology (3176) $3.46 Billion -15.61% 0.30x $146.59 Million
Sagittarius Life Science (3205) $588.38 Million -12.60% 0.26x $112.36 Million
Genovate Biotechnology Co Ltd (4130) $2.25 Billion 1.74% 0.18x $112.45 Million

About Visgeneer

TWO:4197 Taiwan Biotechnology
Market Cap
$8.18 Million
NT$259.56 Million TWD
Market Cap Rank
#27535 Global
#1588 in Taiwan
Share Price
NT$8.60
Change (1 day)
-1.15%
52-Week Range
NT$8.20 - NT$19.00
All Time High
NT$28.80
About

Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cr… Read more